Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

AVEO PHARMACEUTICALS, INC. (AVEO)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 11:25pm CET

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to [email protected], or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
[email protected]
http://www.rigrodskylong.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AVEO PHARMACEUTICALS, INC.
02:21pAVEO PHARMACEUTICALS, INC. : Today’s Research Reports on Trending Tickers: AVEO ..
AC
02/16AVEO PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financial..
AQ
02/14AVEO PHARMACEUTICALS, INC. : Blog Exposure - AVEO Announced Positive NICE Recomm..
AC
02/12AVEO PHARMACEUTICALS : Dwindles on Official Nod on Cancer Treatment
AQ
02/12AVEO PHARMACEUTICALS : Oncology and EUSA Pharma Announce Encouraging Preliminary..
AQ
02/12AVEO PHARMACEUTICALS : Announces EUSA Pharma Granted Positive NICE Recommendatio..
BU
02/10AVEO ONCOLOGY : and EUSA Pharma Announce Encouraging Preliminary Results from Ph..
BU
02/07AVEO ONCOLOGY : to Present at Upcoming Conferences
BU
02/02AVEO PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Unregiste..
AQ
02/02AVEO PHARMACEUTICALS : Announces Appointment of John H. Johnson to Board of Dire..
AQ
More news
News from SeekingAlpha
02/16AVEO Pharma inks stock sales agreement with Leerink 
02/13ROTY EDITION 1 VOLUME 78 : Simplify Your Decision-Making And Stick To Guidelines 
02/13YOUR DAILY PHARMA SCOOP : A Look At Celldex, BeiGene Data, Axovant Announces Cha.. 
02/133 THINGS IN BIOTECH YOU SHOULD LEARN : February 12, 2018 
02/12WEEK 7 BREAKOUT FORECAST :   Short-Term Picks To Give You An Edge 
Financials ($)
Sales 2017 11,1 M
EBIT 2017 -22,4 M
Net income 2017 -73,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 31,3x
Capi. / Sales 2018 29,5x
Capitalization 348 M
Chart AVEO PHARMACEUTICALS, INC.
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Technical analysis trends AVEO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 5,67 $
Spread / Average Target 93%
EPS Revisions
Managers
NameTitle
Michael P. Bailey President, Chief Executive Officer & Director
Matthew D. Dallas Chief Financial Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AVEO PHARMACEUTICALS, INC.4.30%348
GILEAD SCIENCES12.98%105 375
VERTEX PHARMACEUTICALS7.42%39 931
REGENERON PHARMACEUTICALS-14.08%34 113
BIOVERATIV INC92.71%11 232
GENMAB-0.97%10 271